---
title: "Echinacea purpurea - Evidence-Based Clinical Monograph"
category: "Herbal Medicine Monographs"
subcategory: "Immune Support"
botanical_name: "Echinacea purpurea"
common_names: ["Purple Coneflower", "Echinacea"]
tags: ["respiratory infections", "common cold", "influenza", "pediatric", "immune system", "antiviral", "drug interactions", "CYP450"]
evidence_level: "Mixed - Preparation-Dependent"
last_updated: "2025-11-05"
source_verification: "PubMed Verified"
clinical_use: "Respiratory Tract Infection Prevention and Treatment"
corrections_made: ["NNT corrected to 10-11", "CYP3A4 induction corrected to 34%"]
---



# **Echinacea (Echinacea purpurea) — Evidence-Based Clinical Monograph**

## **Table of Contents**

\-(\#clinician-tldr)

* Pharmacology & Mechanism of Action  
  \-(\#key-bioactive-constituents)  
  * \-(\#direct-antiviral-mechanisms)  
    \-(\#pharmacokinetics-adme)  
    \-(\#absorption--bioavailability)  
    \-(\#metabolism--drug-interactions)  
    \-(\#deconstructing-clinical-trial-ddi-conflicts)  
*   
  * \-(\#dosing--administration)  
    \-(\#dosing--standardization-table)  
    \-(\#safety--toxicology)  
  * \-(\#safety-in-special-populations-pediatrics-pregnancy)  
    \-(\#safety-table)  
    \-(\#drug-interactions)  
    \-(\#interactions-table)  
    \-(\#clinical-decision-rules-ifthenbecause)  
    \-(\#protocol-cards-condition-specific)  
    \-(\#protocol-1-pediatric-rti-complication-prevention)  
    \-(\#protocol-2-adult-influenza-treatment)  
    \-(\#comparative-analysis-vs-standard-of-care)  
    \-(\#vs-oseltamivir-tamiflu)  
    \-(\#vs-symptomatic-care-nsaids-decongestants)  
    \-(\#vs-other-supplements-vitamin-c-zinc)  
    \-(\#red-flags--triage-parameters)  
* \-(\#research-frontiers-next-5-years)  
  \-(\#case-studies--clinical-pearls)  
  \-(\#traditional-use)  
  \-(\#preclinical-data)  
  \-(\#source-audit-log-summary-table)  
  \-(\#bibliography)

## **Clinician TL;DR**

* **Efficacy:** The clinical efficacy of *Echinacea* is **entirely preparation-dependent.** This is the single most important clinical takeaway. Meta-analyses and RCTs are in sharp conflict, with this heterogeneity being the primary confounder.  
* **Adult URTI/Cold:** Evidence is contradictory. Some SR/MAs show benefit (e.g., 1.4-day reduction in duration), while the largest Cochrane review and major RCTs (e.g., Barrett 2010, n=719) find the evidence weak, inconsistent, or non-significant. The positive data points toward specific alcoholic extracts, not the herb in general.  
* **Pediatric URTI:** Evidence is also in direct conflict, but explainable. A major RCT (Taylor 2003, n=524) using **pressed juice** found **no efficacy** and an **increased risk of rash** (7.1% vs 2.7%). Conversely, a robust RCT (Ogal 2021, n=201) using a specific **alcoholic extract** (Echinaforce® Junior) found a **significant reduction in antibiotic use (NNT≈10-11)** and *no* increased rash risk.  
* **Influenza:** A large RCT (Rauš 2015, n=473) found a specific *E. purpurea* hot drink (Echinaforce®) **non-inferior to oseltamivir** for recovery time, with a **superior safety profile** (fewer GI adverse events).  
* **Safety:** Generally well-tolerated. Primary AEs are mild/transient GI upset and allergic reactions (rash), especially in atopic individuals (Asteraceae allergy). The pediatric rash signal appears specific to pressed juice preparations.  
* **Interactions (High Risk):** The *in vivo* human data (Gorski 2004\) is the critical guide, not *in vitro* data. Clinicians must assume *E. purpurea* (especially root extracts) is a:  
  1. **Moderate CYP1A2 Inhibitor:** (27% decrease in caffeine clearance). May *increase* levels of theophylline, tizanidine, olanzapine.  
  2. **Hepatic CYP3A4 Inducer:** (34% increase in midazolam clearance). May *decrease* levels of oral contraceptives, statins, and some antiretrovirals.  
* **Clinical Bottom Line:** Do not recommend "Echinacea." Clinical decisions must be based on specific, standardized, and clinically-trialed preparations. The evidence supports *only* specific alcoholic extracts for pediatric RTI/antibiotic prevention and influenza treatment. Other preparations have been proven ineffective.

## **Pharmacology & Mechanism of Action**

### **Key Bioactive Constituents**

#### **Scope**

This section details the primary compound classes responsible for *Echinacea purpurea's* pharmacological effects, which vary based on plant part and extraction solvent.  
*Echinacea's* pharmacology is defined by three primary classes of bioactive compounds. The concentration and presence of these compounds differ significantly based on the plant part used (root vs. aerial parts) and, most critically, the extraction method.

1. **Alkamides (Lipophilic):** These N-alkylamides are characteristic of the roots (up to 6 mg/g) but are also present in aerial parts. They are considered key drivers of immunomodulatory and anti-inflammatory effects. Alkamides are highly soluble in alcohol (ethanol) but poorly soluble in water.  
2. **Caffeic Acid Derivatives (Hydrophilic):** This class includes chicoric acid (also spelled cichoric acid) and caftaric acid. Chicoric acid is found in high concentrations in the aerial parts (leaves and flowers).  
3. **Polysaccharides (Hydrophilic):** These are high-molecular-weight compounds, such as arabinogalactans, primarily found in the pressed juice of aerial parts.

The choice of extraction method dictates the final pharmacological profile. A hot water infusion (tea) or a fresh-pressed juice preparation will be rich in hydrophilic compounds (polysaccharides, caffeic acid derivatives) but poor in lipophilic alkamides. Conversely, an alcohol-based tincture or extract (e.g., 65% ethanol) will be rich in alkamides. This fundamental chemical difference is the primary driver of the contradictory results seen in clinical trials. A pressed juice and an alcoholic extract are, pharmacologically, two different medicines.

#### **Bottom Line**

The key active compounds are alkamides (alcohol-soluble) and polysaccharides (water-soluble). The choice of extraction solvent (alcohol vs. water/juice) determines the final chemical profile and, consequently, its clinical effect.

### **Immunomodulatory Mechanisms**

#### **Scope**

This section covers the "immune-boosting" mechanisms, which are largely driven by polysaccharides and alkamides via two distinct pathways.  
*Echinacea's* reputation as an "immune stimulant" is supported by preclinical data, but the mechanisms are specific.

1. **Macrophage Activation:** Fresh-pressed juice (rich in polysaccharides) and purified polysaccharides have been shown to stimulate cytokine production (e.g., IL-1, IL-10, TNF-α) in human and murine macrophages. This activation of the innate immune system (e.g., phagocytosis) is a primary MOA for polysaccharide-rich preparations.  
2. **Cannabinomimetic (CB2) Pathway:** Alkamides have been shown to be effective on the cannabinoid receptor type 2 (CB2). CB2 receptors are expressed primarily on immune cells (not in the brain) and are non-psychotropic. This alkamide-receptor binding provides a modern, plausible mechanism for the specific anti-inflammatory and immunomodulatory effects of alkamide-rich (alcoholic) extracts.

The CB2-binding mechanism is particularly noteworthy, as it links *Echinacea* to the endocannabinoid system, which is also involved in mood and anxiety. This pharmacological rationale provided the basis for preliminary trials on *Echinacea* for anxiety , suggesting the hypothesis was not random but based on this specific alkamide-receptor interaction.

#### **Bottom Line**

*Echinacea* exerts immunomodulation via two distinct pathways: non-specific macrophage activation by polysaccharides (from pressed juice) and specific CB2 receptor binding by alkamides (from alcoholic extracts).

### **Direct Antiviral Mechanisms**

#### **Scope**

This section details the mechanisms by which *Echinacea* compounds (primarily polyphenols) directly interfere with viral life cycles, independent of host immune modulation.  
Beyond immunomodulation, *Echinacea* preparations possess direct antiviral properties. This mechanism is multi-target and provides a dual-action rationale for its use in URTIs.

1. **Inhibition of Viral Entry:** Caffeic acid derivatives (like chicoric acid) and flavonoids can bind to viral surface proteins (e.g., hemagglutinin) or host cell receptors. This action physically blocks viral entry and has been demonstrated *in vitro* against herpes simplex, influenza, and rhinovirus.  
2. **Inhibition of Viral Replication:** Certain compounds can penetrate the host cell and inhibit key viral enzymes. Chicoric acid, for example, is a known inhibitor of HIV-1 integrase, preventing the virus from integrating its DNA into the host genome.  
3. **Inhibition of Virus Release:** Polyphenols may also disrupt the final stages of viral assembly and budding of new virions from the host cell.

One *in vitro* study found the MIC100 (minimum concentration to inactivate 100% of the virus) to be 2.5 µg/mL for capsule-derived extracts but 2.2 µg/mL for tea brewed at 80 °C. This finding that a hot tea preparation may have *superior* local antiviral activity provides a pharmacological rationale for the positive RCT by Rauš (2015), which specifically utilized a *hot drink* preparation for influenza.

#### **Bottom Line**

*Echinacea* is not just an "immune stimulant"; it possesses direct antiviral properties by blocking viral entry and inhibiting replication, providing a dual mechanism against URTIs.

## **Pharmacokinetics (ADME)**

### **Absorption & Bioavailability**

#### **Scope**

This section analyzes the limited human data on the absorption and distribution of *Echinacea's* active compounds.  
Human pharmacokinetic (PK) data for *Echinacea* is sparse and incomplete. The most robust data exists for the alkamides, which are considered the most likely candidates for *systemic* effects.

* **Alkamides:** The oral bioavailability of alkamides is established. They are lipophilic, diffuse through Caco-2 monolayers, and are detected in the bloodstream after oral administration in humans.  
* **Rapid Absorption:** One study noted that alkamides in lozenges are rapidly absorbed through the buccal and esophageal membranes. This implies that delivery forms that maximize oropharyngeal contact time (lozenges, tinctures held sublingually, or "gargling" a hot drink) may provide a rapid local *and* systemic effect superior to a swallowed tablet.  
* **Data Gaps:** Comprehensive human PK data for hydrophilic compounds (chicoric acid, polysaccharides) is largely absent. It is unknown to what extent these compounds are absorbed systemically versus acting locally on the gut-associated lymphoid tissue (GALT) before degradation.

#### **Bottom Line**

Alkamides are orally bioavailable and rapidly absorbed, even via buccal membranes. Comprehensive human PK data for other constituents is a major research gap, limiting our understanding of the plant's full systemic effects.

### **Metabolism & Drug Interactions**

#### **Scope**

This section details the *in vivo* human data on *Echinacea's* effects on cytochrome P450 (CYP) enzymes, a critical safety concern for clinicians.  
This is the most critical and complex aspect of *Echinacea's* profile. The *in vitro* data is extensive, often contradictory, and a poor predictor of *in vivo* effects. The most reliable clinical guidance comes from a human probe-drug study (Gorski et al., 2004\) that administered *E. purpurea* root extract to healthy volunteers.  
The Gorski et al. *in vivo* human findings are as follows :

* **CYP1A2 (Inhibition):** *Echinacea* **significantly inhibited** CYP1A2 activity, demonstrated by a **27% decrease in caffeine clearance**. This suggests a high risk of toxicity for narrow therapeutic index (NTI) CYP1A2 substrates (e.g., theophylline, tizanidine).  
* **CYP3A4 (Induction/Inhibition):** *Echinacea* has a complex, tissue-specific effect. It **inhibited intestinal CYP3A4** but **induced hepatic CYP3A4**, demonstrated by a **34% increase in the systemic clearance of midazolam**.  
* **CYP2C9 (Inhibition):** Showed a trend toward inhibition (a 12% decrease in tolbutamide clearance), though this was not statistically significant.

The induction of hepatic CYP3A4 is a major clinical concern, as it can lead to the **therapeutic failure** of numerous critical drugs, including oral contraceptives, statins, and immunosuppressants.

#### **Bottom Line**

Clinicians must disregard *in vitro* data. Based on the best available *in vivo* human data, *E. purpurea* root extract is a moderate **CYP1A2 inhibitor** (risk of toxicity) and a moderate **hepatic CYP3A4 inducer** (risk of therapeutic failure).

### **Deconstructing Clinical Trial DDI Conflicts**

#### **Scope**

This section resolves the apparent contradictions from subsequent clinical trials that failed to show a CYP3A4 interaction, which has created confusion for clinicians.  
Two subsequent human trials appeared to contradict the Gorski 2004 findings, but these trials are confounded and *do not* disprove the interaction.

1. **Lopinavir/Ritonavir (Penzak 2010):** This RCT found that *Echinacea* did not alter lopinavir/ritonavir (CYP3A4 substrate) levels. However, the study *also* administered a midazolam probe and *confirmed* that *Echinacea* **did induce CYP3A4 activity**. The interaction was **masked** because ritonavir is a *potent* CYP3A4 inhibitor that "overpowered" *Echinacea's* moderate inductive effect. This trial does not demonstrate safety; it demonstrates a known drug-drug-herb interaction.  
2. **Docetaxel (Goey 2013):** This trial in cancer patients found *Echinacea* (20 drops, 3x/day) did not alter docetaxel (CYP3A4 substrate) PK. However, pharmacokinetic analysis of the patients showed that plasma levels of the key alkamides were **undetectable or \<0.08 ng/mL**. This was a trial of an *sub-therapeutic dose* and cannot be used to conclude safety at a clinically effective dose.

#### **Bottom Line**

The negative interaction trials (Penzak 2010, Goey 2013\) are confounded by a potent inhibitor (ritonavir) and sub-therapeutic dosing, respectively. The Gorski 2004 probe-drug study remains the definitive clinical evidence. The risk of CYP1A2 inhibition and CYP3A4 induction is real and must be managed.

## **Human Clinical Evidence**

### **Evidence Map**

#### **Scope**

This table summarizes the highest-quality evidence for *Echinacea's* primary indications, graded according to a standard Evidence Grading Rubric (A, B, C, D).  
**Table: Evidence Map**

| Indication | Grade | Best Study Type | n | Dose/Form | Duration | Primary Outcome | Effect Size (CI/p) | Key PMIDs | Bottom Line |
| :---- | :---- | :---- | :---- | :---- | :---- | :---- | :---- | :---- | :---- |
| **URTI Treatment (Adults)** | **C** | SR/MA | 14 studies | Heterogeneous | Heterogeneous | Duration of cold | WMD \-1.44 days (95% CI \-2.24 to \-0.64; $p=0.01$) |  | **Contradictory.** Positive SR/MA (Shah 2007\) is offset by a large negative RCT (Barrett 2010\) and negative Cochrane Review (Linde 2014\) due to extreme heterogeneity. |
| **URTI Prevention (Adults)** | **C** | SR/MA | 9 studies | Heterogeneous | Heterogeneous | Incidence of cold | OR 0.42 (95% CI 0.25–0.71) |  | **Contradictory.** Shah 2007 found a 58% reduced odds, but the 2014 Cochrane review found no significant prevention effect. |
| **URTI/Complication Prevention (Pediatrics)** | **B-** | RCT | 201 | 400 mg 3x/day (Echinaforce® Junior) | 4 months | Antibiotic Treatment Days | 80.2% reduction (45 vs 216 days; $p \< 0.001$); NNT≈10-11 |  | **Highly preparation-dependent.** A specific alcoholic extract (Ogal 2021\) significantly reduced antibiotic use. A pressed juice (Taylor 2003\) was *ineffective* and *caused rash*. |
| **Influenza Treatment (Adults)** | **B** | RCT | 473 | Echinaforce® Hotdrink (5mL 3-5x/day) | 10 days | Time to recovery | **Non-inferior** to Oseltamivir. Fewer AEs. |  | A single, large, manufacturer-sponsored RCT showed non-inferiority to standard of care with better tolerability. Requires independent replication. |
| **Anxiety Treatment (Adults)** | **D** | RCT | 108 | *E. angustifolia* (EP107™) 40-80 mg/day | 6 weeks | Anxiety scores | No significant difference vs. placebo. |  | A larger RCT failed to replicate earlier positive findings from a small (n=26) trial.\[16\] Evidence does not support use. |
| **Wound Healing (Topical)** | **D** | N/A | 0 | N/A | N/A | Healing time | No human clinical trial data available. | \[1, 11, 17\] | Plausible based on traditional use and preclinical anti-inflammatory data , but lacks any human clinical evidence. |

#### **Bottom Line**

The clinical evidence for *Echinacea* is a case study in preparation-dependent effects. Grade B evidence supports specific alcoholic extracts for pediatric complication prevention (Ogal 2021\) and adult influenza (Rauš 2015). The general use for "common cold" remains Grade C due to conflicting, heterogeneous data.

## **Dosing & Administration**

### **Dosing & Standardization Table**

#### **Scope**

This table provides clinically-trialed dosing regimens for specific, effective preparations. Recommending unstandardized products is not supported by evidence.  
**Table: Dosing & Administration**

| Form | Adult Dose (per dose) | Daily Range | Frequency | Timing | Standardization (% marker) | Equivalency | Clinical Context | Sources (PMIDs) |
| :---- | :---- | :---- | :---- | :---- | :---- | :---- | :---- | :---- |
| **Alcoholic Extract (Echinaforce® Hotdrink)** | 5 mL concentrate | 15-25 mL | **Days 1-3:** 5x/day. **Days 4-10:** 3x/day. | At first sign of symptoms (\<48h) | Hydroethanolic (65% v/v) herb (95%) and root (5%) extract. | 5 mL \= 240mg extract (DER 1:11-12) \+ 276.5mg Elderberry | **Influenza Treatment (Adults).** Non-inferior to Oseltamivir. |  |
| **Alcoholic Extract (Echinaforce® Junior)** | 400 mg tablet | 1200 mg | 3x/day | With meals | Alcoholic *E. purpurea* herb/root extract. | Not specified. | **Pediatric (4-12 yrs) URTI Prevention.** Reduced antibiotic use by 80%. |  |
| **Pressed Juice (Echinacin®)** | Not specified | Not specified | Not specified | Not specified | Pressed juice from *E. purpurea* aerial parts. | Not specified. | **Pediatric (2-11 yrs) URTI Treatment.** Used in Taylor 2003 RCT and found **ineffective** and associated with **rash**. | , |
| ***E. angustifolia*** **Extract (EP107™)** | 20-40 mg | 40-80 mg | 2x/day | Not specified | Standardized extract of *E. angustifolia* roots. | Not specified. | **Anxiety Treatment (Adults).** Used in RCT and found **ineffective** vs. placebo. |  |
| **USP Standardized Powder** | N/A (QC) | N/A (QC) | N/A (QC) | N/A (QC) | **NLT 4.0%** total phenols (caftaric, chicoric, chlorogenic acids); **NLT 0.025%** dodecatetraenoic acid isobutylamides. | N/A | **Quality Control Standard.** This is a QC benchmark, not a clinical dose. |  |

#### **Bottom Line**

Dosing is highly specific to the proprietary extract used in a successful clinical trial. The doses for effective (alcoholic) vs. ineffective (pressed juice, anxiety extract) preparations are not interchangeable.

## **Safety & Toxicology**

### **Overview of Adverse Events**

#### **Scope**

This section reviews the common adverse events (AEs) and overall tolerability reported in human trials.  
*Echinacea* is generally well-tolerated in short-term use. The most commonly reported AEs are mild and transient, primarily gastrointestinal upset (e.g., nausea, stomach pain).  
The most clinically significant risk is allergic reaction. This can manifest as a mild rash or urticaria, but in rare cases, anaphylaxis has been reported. This risk is highest in atopic individuals with known allergies to the Asteraceae (Compositae) family, which includes ragweed, marigolds, and daisies.  
In the large RCTs for effective preparations, the safety profile was superior to the comparator. The Ogal 2021 (pediatric) trial found *fewer* total AEs in the *Echinacea* group than in the Vitamin C control group, a difference attributed to the reduction in RTI complications (e.g., otitis media, bronchitis) and their associated symptoms. Similarly, the Rauš 2015 (influenza) trial reported significantly fewer AEs (especially nausea and vomiting) than the oseltamivir group.

#### **Bottom Line**

The most common AEs are mild GI upset. The most serious risk is allergic reaction (e.g., rash), which is a clear contraindication for patients with Asteraceae allergies. Specific alcoholic extracts have demonstrated a favorable safety profile, with fewer AEs than controls, in large RCTs.

### **Safety in Special Populations (Pediatrics, Pregnancy)**

#### **Scope**

This section analyzes the specific safety signals and contraindications for vulnerable populations, focusing on the conflicting pediatric rash data.  
Pediatrics:  
The safety of Echinacea in children is a critical point of confusion, driven by two high-quality, contradictory RCTs.

1. **The Rash Signal (Pressed Juice):** The Taylor 2003 RCT (n=524) of children 2-11 years old used a **pressed juice** preparation (Echinacin®). This trial found a statistically significant **increased risk of rash** (7.1% in *Echinacea* vs. 2.7% in placebo; $P \=.008$).  
2. **No Rash Signal (Alcoholic Extract):** The Ogal 2021 RCT (n=201) of children 4-12 years old used an **alcoholic extract** (Echinaforce® Junior). This trial found **no increased risk of rash** and reported *fewer* overall AEs than the vitamin C control group.

This is a critical, preparation-dependent safety signal. The risk of rash appears to be associated with the pressed juice preparation, not all *Echinacea* products. Clinicians must not extrapolate the Taylor 2003 safety warning to all preparations.  
Pregnancy:  
One prospective cohort study (Perri 2006\) followed 206 women who used Echinacea during pregnancy (112 in the first trimester) and compared them to a disease-matched control group. The study found no statistical difference in the rate of major malformations. The authors concluded that gestational use of Echinacea during organogenesis is not associated with an increased risk of major malformations.  
Lactation:  
No human data on safety during lactation exists. Caution is advised.  
Autoimmune Disease:  
A theoretical contraindication exists due to immunostimulant properties, but this is debated and lacks clinical data.

#### **Bottom Line**

Pediatric use is associated with a risk of rash *only* for specific (pressed juice) preparations; alcoholic extracts appear safe. Good-quality observational data suggests no teratogenic risk in the first trimester. Use in lactation is not supported by safety data.

### **Safety Table**

**Table: Safety & Adverse Events**

| AE/Concern | Frequency/Severity | Mechanism/Risk Factors | Management | Evidence (PMIDs) |
| :---- | :---- | :---- | :---- | :---- |
| **Allergic Reaction (Rash, Urticaria)** | Common (in peds, 7.1% for pressed juice); Rare (in adults). | IgE-mediated hypersensitivity. **Risk Factor:** Atopy or known allergy to Asteraceae family (ragweed, marigold). | Discontinue use. Treat with antihistamines or supportive care as needed. Contraindicated in known allergy. | \[3, 24\] |
| **Gastrointestinal Upset** | Mild, Transient | Direct mucosal irritation. | Take with food. Self-limiting. |  |
| **Anaphylaxis** | Rare / Case-report level | Severe Type 1 Hypersensitivity. | Discontinue. Immediate medical intervention (epinephrine). Contraindicate. |  |
| **Autoimmune Exacerbation** | Theoretical | (Theoretical) Non-specific immune stimulation. | **Data Gap.** Use with caution in patients with active autoimmune disease (e.g., MS, RA, Lupus). |  |
| **Teratogenicity** | Not observed in humans. | N/A | Prospective cohort study (n=206) found **no increased risk** of major malformations in 1st trimester. |  |

## **Drug Interactions**

### **Interactions Table**

#### **Scope**

This table provides actionable guidance on pharmacokinetic (PK) and pharmacodynamic (PD) interactions, based on the *in vivo* human data from Gorski et al..  
**Table: Pharmacokinetic & Pharmacodynamic Interactions**

| Drug/Class | PK/PD | Mechanism (CYP/Transporter/PD) | Significance | Management | Evidence (PMIDs) |
| :---- | :---- | :---- | :---- | :---- | :---- |
| **CYP1A2 Substrates** (e.g., Theophylline, Tizanidine, Olanzapine, Caffeine) | **PK** | **Inhibition of CYP1A2.** (Human *in vivo* data: 27% decrease in caffeine clearance). | **High.** Can lead to *increased* plasma concentrations and toxicity of the substrate. | Avoid concomitant use, especially with NTI drugs. If unavoidable, requires therapeutic drug monitoring (TDM). | \[8, 12\] |
| **CYP3A4 Substrates** (e.g., Oral contraceptives, Statins, Cyclosporine, CCBs, Docetaxel) | **PK** | **Induction of Hepatic CYP3A4.** (Human *in vivo* data: 34% increase in midazolam clearance). | **High.** Can lead to *decreased* plasma concentrations and **therapeutic failure** of the substrate. | Counsel patients on potential for reduced efficacy (e.g., risk of pregnancy). Monitor for effect (e.g., TDM for cyclosporine). | \[8, 12\], |
| **CYP2C9 Substrates** (e.g., Warfarin, Tolbutamide) | **PK** | **Inhibition of CYP2C9.** (Human *in vivo* data: 12% decrease in tolbutamide clearance; trend). | **Moderate.** Potential to *increase* substrate levels. A trial with Warfarin found a change in S-warfarin clearance but no significant change in INR. | Use with caution. Monitor INR closely if co-administered with Warfarin. |  |
| **Lopinavir/Ritonavir** | **PK** | CYP3A4 Induction. | **Low (Masked).** A human RCT found *no effect*. **Reason:** The induction from *Echinacea* was masked by the *potent inhibition* from Ritonavir. | No dosage change needed. This *cannot* be extrapolated to other antiretrovirals. |  |
| **Immunosuppressants** (e.g., Cyclosporine, Tacrolimus, Azathioprine) | **PD / PK** | **PD:** Theoretical antagonism (immune-stimulation). **PK:** Cyclosporine is a CYP3A4 substrate; *Echinacea* may *induce* its metabolism, lowering levels. | **High (Theoretical PD; High PK).** | **Avoid use.** The combination presents a high-risk antagonism, both by lowering drug levels (PK) and opposing the desired therapeutic effect (PD). | \[12, 23\] |

## **Clinical Decision Rules (IF/THEN/BECAUSE)**

#### **Scope**

This section provides actionable rules to navigate *Echinacea's* complex efficacy and safety profile.

* **Rule 1: Pediatric RTI**  
  * **IF** a parent asks about *Echinacea* for a child (4-12 yrs) with recurrent RTIs...  
  * **THEN** recommend *only* a specific, standardized **alcoholic extract** (e.g., Echinaforce® Junior, 400mg 3x/day) and explicitly advise *against* **pressed juice** preparations.  
  * **BECAUSE** the alcoholic extract has robust RCT evidence (Ogal 2021\) for reducing antibiotic use (NNT≈10-11) and complications *without* causing rash, while the pressed juice preparation (Taylor 2003\) was proven *ineffective* and carries a significant risk of rash (NNH \~23).  
* **Rule 2: Adult Influenza**  
  * **IF** an adult patient presents with \<48h of influenza symptoms and is seeking alternatives to oseltamivir (e.g., due to cost or history of GI side effects)...  
  * **THEN** a specific hot drink preparation (Echinaforce® Hotdrink, 5mL, 3-5x/day) is a reasonable option.  
  * **BECAUSE** a large RCT (Rauš 2015\) found it **non-inferior** to oseltamivir for recovery time and **superior** in its safety profile (fewer AEs).  
* **Rule 3: CYP1A2 Interaction**  
  * **IF** a patient is taking a narrow therapeutic index CYP1A2 substrate (e.g., Theophylline, Tizanidine, Olanzapine)...  
  * **THEN** *Echinacea* (especially root extracts) should be **contraindicated** or used only with therapeutic drug monitoring.  
  * **BECAUSE** human *in vivo* data confirms *Echinacea* is a moderate **CYP1A2 inhibitor** (27% decrease in caffeine clearance), creating a high risk of substrate toxicity.  
* **Rule 4: CYP3A4 Interaction**  
  * **IF** a patient is taking a critical CYP3A4 substrate (e.g., oral contraceptives, cyclosporine, tacrolimus)...  
  * **THEN** they must be counseled on a significant risk of **therapeutic failure**.  
  * **BECAUSE** human *in vivo* data confirms *Echinacea* is a hepatic **CYP3A4 inducer** (34% increase in midazolam clearance), which accelerates substrate metabolism and *reduces* drug levels.

#### **Bottom Line**

Clinical use is governed by two principles: 1\) Efficacy is limited to specific alcoholic extracts, and 2\) Safety is limited by significant CYP1A2 inhibition and CYP3A4 induction.

## **Protocol Cards (Condition-Specific)**

### **Protocol 1: Pediatric RTI Complication Prevention**

#### **Scope**

This protocol is for reducing the incidence of complications (otitis media, sinusitis) and antibiotic use in children (4-12 yrs) with recurrent RTIs, based on the Ogal 2021 RCT.

* **Protocol:**  
  * **Indication:** Prevention of URTI complications and antibiotic use in children 4-12 yrs.  
  * **Preparation:** Echinaforce® Junior (alcoholic *E. purpurea* herb/root extract).  
  * **Dose:** 400 mg tablet.  
  * **Regimen:** 1 tablet (400 mg) TID (3x/day).  
  * **Duration:** Up to 4 months (as per trial).  
  * **Evidence Grade:** B. (Significant effect, NNT≈10-11, but a single, well-conducted RCT).

#### **Bottom Line**

This specific regimen demonstrated an 80.2% reduction in antibiotic treatment days and a 65% reduction in RTI complications.

### **Protocol 2: Adult Influenza Treatment**

#### **Scope**

This protocol is for the acute treatment of influenza symptoms in adults, initiated within 48 hours of onset, based on the Rauš 2015 RCT.

* **Protocol:**  
  * **Indication:** Acute influenza treatment (symptom onset \<48h).  
  * **Preparation:** Echinaforce® Hotdrink (alcoholic *E. purpurea* herb/root extract \+ Elderberry).  
  * **Dose:** 5 mL of concentrate (diluted in hot water).  
  * **Regimen:**  
    * Days 1-3: 5 mL, 5 times per day.  
    * Days 4-10: 5 mL, 3 times per day.  
  * **Duration:** 10 days total.  
  * **Evidence Grade:** B. (Non-inferior to Oseltamivir, better tolerated, but a single, manufacturer-sponsored trial).

#### **Bottom Line**

This protocol was shown to be as effective as oseltamivir for recovery from influenza, with a statistically non-significant trend toward fewer complications (2.5% vs 6.5%).

## **Comparative Analysis (vs. Standard of Care)**

### **vs. Oseltamivir (Tamiflu)**

#### **Scope**

Direct comparison for the treatment of acute influenza.  
The Rauš 2015 (n=473) double-blind, double-dummy RCT is the key dataset.

* **Efficacy:** Echinaforce Hotdrink was **non-inferior** to Oseltamivir (75mg). Recovery at Day 10 was 90.1% vs 84.8%, respectively.  
* **Safety:** Echinaforce Hotdrink was **superior in tolerability**. Fewer AEs were observed, particularly nausea and vomiting, which are common with Oseltamivir. Complications (e.g., sinusitis, bronchitis) were lower in the *Echinacea* group, though this finding was not statistically significant (2.46% vs 6.45%; $P \= 0.076$).

For an otherwise healthy adult with uncomplicated influenza, the *Echinacea* preparation offers a comparable recovery trajectory with a significantly lower burden of adverse effects, making it a viable clinical alternative.

#### **Bottom Line**

A specific *E. purpurea* hot drink (Echinaforce®) demonstrated non-inferior efficacy and superior tolerability compared to oseltamivir in a large RCT.

### **vs. Symptomatic Care (NSAIDs, Decongestants)**

#### **Scope**

Comparison for the treatment of the common cold (URTI).  
Standard of care (SOC) for URTIs (NSAIDs, decongestants) is purely symptomatic; it does not shorten illness duration or prevent complications.

* **Comparative Efficacy:** *Echinacea* (effective preps) offers a *potential* (Grade B/C) reduction in *duration* (Shah 2007: 1.4 days) and *prevention of complications/antibiotic use* (Ogal 2021: 80% reduction). This is a therapeutic goal that SOC does not address. Ineffective *Echinacea* preps (e.g., Taylor 2003, Barrett 2010\) offer no benefit over placebo, and thus are inferior to SOC (which at least provides symptomatic relief).  
* **Comparative Safety:** The risk profile of short-term *Echinacea* (mild GI upset, rash) is different from, and arguably safer than, the risks of NSAIDs (GI bleed, renal toxicity, cardiovascular risk) or decongestants (tachycardia, hypertension).

#### **Bottom Line**

Effective *Echinacea* preparations (e.g., Echinaforce®) offer a clinically superior goal (duration reduction, complication prevention) compared to purely symptomatic care. Ineffective preparations are inferior to SOC.

### **vs. Other Supplements (Vitamin C, Zinc)**

#### **Scope**

Comparison against other common supplements for URTI.

* **vs. Vitamin C:** Vitamin C (0.5-2g/day) is largely ineffective for *prevention* in the general population but may reduce *duration* by \~14% in children. The Ogal 2021 RCT used 50mg Vitamin C as a *control* (not a placebo) and found *Echinacea* *vastly superior* for preventing colds, complications, and antibiotic use.  
* **vs. Zinc:** Zinc lozenges are also used to reduce cold duration, with a different (local/ionic) proposed MOA. The evidence is also conflicting. No high-quality head-to-head trials comparing *Echinacea* and Zinc were identified.

#### **Bottom Line**

A specific *Echinacea* preparation (Echinaforce®) was proven significantly more effective than Vitamin C in a large pediatric RCT. No comparative data exists for Zinc.

## **Red Flags & Triage Parameters**

* **Allergic Reaction (Early):**  
  * **Red Flag:** Patient reports tingling/burning of the tongue, mouth, or throat immediately after dosing.  
  * **Triage:** This is an early sign of a hypersensitivity reaction. Instruct patient to **discontinue immediately**. Monitor for progression to urticaria or dyspnea.  
* **High-Risk Patient (Allergy):**  
  * **Red Flag:** Patient has a known severe allergy to ragweed, marigolds, daisies, or other Asteraceae-family plants.  
  * **Triage:** **Contraindicate** *Echinacea* use. The risk of cross-reactive anaphylaxis is high.  
* **High-Risk Patient (Drug Interactions):**  
  * **Red Flag:** Patient is on a narrow therapeutic index (NTI) drug, especially Theophylline, Olanzapine, Cyclosporine, or Warfarin.  
  * **Triage:** **Contraindicate** *Echinacea* use. The risk of a clinically significant drug interaction via CYP1A2 inhibition or CYP3A4 induction is high and unpredictable.  
* **Pediatric Rash:**  
  * **Red Flag:** A child develops a new-onset maculopapular rash while taking an *Echinacea* product.  
  * **Triage:** **Discontinue** the product. Note the *type* of product (pressed juice vs. alcoholic extract) in the patient's chart.  
* **Lack of Efficacy:**  
  * **Red Flag:** Patient has been taking *Echinacea* for \>48h for an acute cold with no improvement in symptoms.  
  * **Triage:** This is a therapeutic failure. Instruct patient to cease use (as it is ineffective) and switch to standard symptomatic care. This is likely due to an ineffective, non-trialed preparation.

## **Quality & Adulteration Checklist**

The primary quality issue with *Echinacea* is not just adulteration, but the extreme **heterogeneity** in marketed products. A "bottle of *Echinacea*" could be *E. purpurea* root, *E. angustifolia* root, *E. purpurea* aerial parts, or a mix, extracted with 20% alcohol, 65% alcohol , or just pressed juice. These are not interchangeable products, which explains the chaotic state of the clinical literature.  
**Table: Quality/Adulteration Checklist**  
**Clinical Quality Checklist:**

1. \[ \] **Verify Species & Part:** Is it *Echinacea purpurea*? Is it root, aerial parts, or both? (Clinical data supports herb/root combos).  
2. \[ \] **Verify Extraction:** Is it an **alcoholic extract** (e.g., 65% ethanol) or a **pressed juice**? (Clinical data strongly favors alcoholic extracts).  
3. \[ \] **Verify Standardization:** Does the label (or Certificate of Analysis) specify standardization to **alkamides** and **phenols** per the USP monograph?.  
4. \[ \] **Verify Product:** Is this the *exact brand* used in a positive RCT (e.g., Echinaforce®)? If not, efficacy cannot be assumed.

## **Research Frontiers (Next 5 Years)**

1. **Independent Replication of Ogal 2021:** The NNT of approximately 10-11 to prevent an antibiotic course in children is a major public health claim from a single (though well-done) RCT. It *must* be independently replicated by an unaffiliated research group to become Grade A evidence.  
2. **Independent Replication of Rauš 2015:** Similarly, the finding of non-inferiority to oseltamivir is transformative for influenza treatment but requires independent replication to separate it from manufacturer sponsorship.  
3. **Definitive Human PK/DDI Trial:** A comprehensive, multi-dose human trial using a "cocktail" of probe substrates (caffeine for 1A2, midazolam for 3A4, tolbutamide/flurbiprofen for 2C9) is urgently needed to resolve the complex *in vivo* CYP interaction profile and create definitive clinical guidelines.  
4. **Alkamides as Anxiolytic Leads:** Despite the negative EP107™ RCT, the CB2-binding MOA of alkamides remains a highly promising target. Research should shift from "whole extracts" for anxiety to isolating specific, highly-bioavailable alkamides as potential new drug leads.  
5. **Head-to-Head: Echinaforce® vs. Zinc:** A large, pragmatic RCT comparing the top *Echinacea* preparation (Echinaforce®) against zinc gluconate lozenges and placebo for acute URTI treatment would resolve a major clinical question for patients.

## **Case Studies & Clinical Pearls**

* **Pearl 1: The "Tingle" is a QC Marker:** The tingling or burning sensation in the mouth is not necessarily an allergy; it is a known organoleptic (sensory) effect of the alkamides. Some herbalists use this "tingle" as an *informal* quality check for alkamide-rich root tinctures. However, clinicians must be able to differentiate this from a true hypersensitivity reaction, which would also involve erythema, pruritus, or edema.  
* **Pearl 2: Preparation, Preparation, Preparation:** The *Echinacea* debate is a "failure to communicate." The media (and many clinicians) cite the negative Barrett 2010 and Taylor 2003 trials as "proof *Echinacea* doesn't work." The astute clinician understands this *proves* that *those specific preparations* don't work. The positive Ogal 2021 and Rauš 2015 trials prove that *other specific preparations* do. All clinical recommendations must flow from this distinction.  
* **Case Study (Hypothetical):** A 35-year-old female on oral contraceptives (OCPs, a CYP3A4 substrate) takes a high-dose *Echinacea* root extract (a CYP3A4 inducer) for 2 weeks as a cold prevention. She experiences breakthrough bleeding. This is a *plausible* drug-herb interaction caused by *Echinacea* inducing the hepatic metabolism of the OCPs, lowering their systemic levels and leading to therapeutic failure.  
* **Case Study (Hypothetical):** A 6-year-old with recurrent otitis media (3 courses of amoxicillin in 6 months) is placed on Echinaforce Junior (400mg TID) by his pediatrician for 4 months. The patient experiences only one mild cold and requires no antibiotics. This outcome reflects the NNT of approximately 10-11 reported in the Ogal 2021 trial.

## **Traditional Use**

*Echinacea* species (esp. *E. angustifolia*) were widely used by Great Plains Indigenous tribes (e.g., Lakota, Cheyenne, Sioux). It was used for a vast range of ailments, including as a pain reliever (toothaches), for snakebites, and for infections/wounds.  
This use was adopted into Eclectic medicine in the 19th century, leading to its modern reputation as an "immune stimulant". The European Medicines Agency (EMA) recognizes the "traditional use" (not "well-established use") of *E. purpurea* herb juice for the treatment of small, superficial wounds. This is based on plausibility and long-standing use, *not* on modern clinical trial data.

## **Preclinical Data**

Preclinical data provides the biological plausibility for the positive clinical trials in URTIs. *E. purpurea* extracts show direct antiviral activity against influenza, herpes simplex, and rhinovirus *in vitro* by blocking viral entry and replication.  
The extracts also demonstrate *in vitro* bactericidal properties against respiratory pathogens like *Streptococcus pyogenes* and *Haemophilus influenzae*. In cell models, *Echinacea* compounds (chicoric acid, alkamides) modulate anti-inflammatory pathways, including NF-κB expression. Polysaccharides from *E. pallida* and *E. purpurea* roots also showed anti-inflammatory and wound-healing properties in preclinical models.

## **Source Audit Log (Summary Table)**

| Source ID(s) | PMID / DOI | Study Type | Key Contribution |
| :---- | :---- | :---- | :---- |
| \[19\] |  | SR/MA (Shah 2007\) | **Positive** URTI data (Adults): 1.4-day duration reduction, 58% reduced incidence. |
| \[34\] |  | SR/MA (Linde 2014\) | **Negative/Weak** URTI data: Evidence inconsistent, pooling "methodologically questionable." |
| \[35\] |  | RCT (Barrett 2010\) | **Negative** URTI data: Large (n=719) trial found no significant benefit vs. placebo. |
| \[21, 36\] |  | RCT (Ogal 2021\) | **Positive** Pediatric data (Echinaforce®): 80% reduction in antibiotic use; NNT≈10-11. No rash. |
| \[37\] |  | RCT (Taylor 2003\) | **Negative** Pediatric data (Pressed Juice): No efficacy and **increased risk of rash** (7.1% vs 2.7%). |
| \[18, 38\] |  | RCT (Rauš 2015\) | **Positive** Influenza data: **Non-inferior** to Oseltamivir with better safety profile. Confirmed dosing. |
|  |  | Human PK Study (Gorski 2004\) | **Critical Interaction Data:** Confirmed *in vivo* **CYP1A2 Inhibition** and **CYP3A4 Induction**. |
|  |  | RCT (Holliday 2021\) | **Negative** Anxiety data (*E. angustifolia*): (n=108) trial found no benefit vs. placebo. |
|  |  | Observational (Perri 2006\) | **Positive** Pregnancy Safety data: Prospective cohort (n=206) found no increased risk of malformations. |
|  | N/A (USP Monograph) | Compendial Standard | **Quality Control Data:** Defines USP standard (NLT 4.0% phenols, NLT 0.025% alkamides). |

## **Bibliography**

* Shah SA, et al. Evaluation of echinacea for the prevention and treatment of the common cold: a meta-analysis. *Lancet Infect Dis*. 2007;7(7):473-80. (DOI: 10.1016/S1473-3099(07)70160-3)  
* Karsch-Völk M, et al. Echinacea for preventing and treating the common cold. *Cochrane Database Syst Rev*. 2014;(2):CD000530. (DOI: 10.1002/14651858.CD000530.pub3)  
* Barrett B, et al. Echinacea for treating the common cold: a randomized trial. *Ann Intern Med*. 2010;153(12):769-77. (DOI: 10.7326/0003-4819-153-12-201012210-00003)  
* Ogal M, et al. Echinacea reduces antibiotic usage in children through respiratory tract infection prevention: a randomized, blinded, controlled clinical trial. *Eur J Med Res*. 2021;26(1):33. (DOI: 10.1186/s40001-021-00499-6)  
* Taylor JA, et al. Efficacy and safety of echinacea in treating upper respiratory tract infections in children: a randomized controlled trial. *JAMA*. 2003;290(21):2824-30. (DOI: 10.1001/jama.290.21.2824)  
* Rauš K, et al. Effect of an Echinacea-Based Hot Drink Versus Oseltamivir in Influenza Treatment: A Randomized, Double-Blind, Double-Dummy, Multicenter, Noninferiority Clinical Trial. *Curr Ther Res Clin Exp*. 2015;77:66-72. (DOI: 10.1016/j.curtheres.2015.04.001)  
* Gorski JC, et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. *Clin Pharmacol Ther*. 2004;75(1):89-100. (DOI: 10.1016/j.clpt.2003.09.013)  
* Holliday K, et al. An investigation into the anxiety-relieving and mood-enhancing effects of Echinacea angustifolia (EP107™): A randomised, double-blind, placebo-controlled study. *J Affect Disord*. 2021;293:229-237. (DOI: 10.1016/j.jad.2021.06.054)  
* Perri D, et al. Safety and efficacy of echinacea (Echinacea angustifolia, E. purpurea and E. pallida) during pregnancy and lactation. *Can J Clin Pharmacol*. 2006;13(3):e262-7.  
* Penzak SR, et al. Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects. *J Clin Pharmacol*. 2010;50(5):534-40. (DOI: 10.1177/0091270009355291)  
* Goey AK, et al. The effect of Echinacea purpurea on the pharmacokinetics of docetaxel. *Br J Clin Pharmacol*. 2013;76(3):467-74. (DOI: 10.1111/bcp.12152)  
* Wu G, et al. Efficacy and safety of Echinacea purpurea in treating upper respiratory infections and complications of otitis media in children: Systematic review and meta-analysis. *Int J Plant Based Pharm*. 2024;4(2):90-100.  
* Weber W, et al. Echinacea purpurea for prevention of upper respiratory tract infections in children. *J Altern Complement Med*. 2005;11(6):1021-6. (DOI: 10.1089/acm.2005.11.1021)  
* Sperber SJ, et al. Echinacea purpurea for prevention of experimental rhinovirus colds. *Clin Infect Dis*. 2004;38(10):1367-71. (DOI: 10.1086/383604)

#### **Works cited**

1. Assessment report on Echinacea purpurea (L.) Moench., herba recens | EMA, accessed November 5, 2025, [https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-echinacea-purpurea-l-moench-herba-recens\_en.pdf](https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-echinacea-purpurea-l-moench-herba-recens_en.pdf)  
2. Clinical Implications of Herbal Supplements in Conventional Medical Practice: A US Perspective \- PMC \- NIH, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9375827/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9375827/)  
3. The Safety of Herbal Medicinal Products Derived from Echinacea Species \- ResearchGate, accessed November 5, 2025, [https://www.researchgate.net/publication/7885382\_The\_Safety\_of\_Herbal\_Medicinal\_Products\_Derived\_from\_Echinacea\_Species](https://www.researchgate.net/publication/7885382_The_Safety_of_Herbal_Medicinal_Products_Derived_from_Echinacea_Species)  
4. Echinacea purpurea: Pharmacology, phytochemistry and analysis methods \- ResearchGate, accessed November 5, 2025, [https://www.researchgate.net/publication/276060286\_Echinacea\_purpurea\_Pharmacology\_phytochemistry\_and\_analysis\_methods](https://www.researchgate.net/publication/276060286_Echinacea_purpurea_Pharmacology_phytochemistry_and_analysis_methods)  
5. Echinacea purpurea (L.) Moench: Biological and Pharmacological Properties. A Review, accessed November 5, 2025, [https://www.mdpi.com/2223-7747/11/9/1244](https://www.mdpi.com/2223-7747/11/9/1244)  
6. Phytochemistry, Mechanisms, and Preclinical Studies of Echinacea Extracts in Modulating Immune Responses to Bacterial and Viral Infections: A Comprehensive Review \- PubMed Central, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11504277/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11504277/)  
7. A strategy for test article selection and phytochemical characterization of Echinacea purpurea extract for safety testing \- PMC \- NIH, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC7079738/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7079738/)  
8. Echinacea purpurea: Pharmacology, phytochemistry and analysis ..., accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC4441164/](https://pmc.ncbi.nlm.nih.gov/articles/PMC4441164/)  
9. Effect of an Echinacea-Based Hot Drink Versus Oseltamivir in Influenza Treatment: A Randomized, Double-Blind, Double-Dummy, Multicenter, Noninferiority Clinical Trial \- PubMed Central, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC4528044/](https://pmc.ncbi.nlm.nih.gov/articles/PMC4528044/)  
10. An investigation into the anxiety-relieving and mood-enhancing effects of Echinacea angustifolia (EP107™): A randomised, double-blind, placebo-controlled study \- PubMed, accessed November 5, 2025, [https://pubmed.ncbi.nlm.nih.gov/34217960/](https://pubmed.ncbi.nlm.nih.gov/34217960/)  
11. Assessment report on Echinacea purpurea (L.) Moench, radix | EMA, accessed November 5, 2025, [https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-echinacea-purpurea-l-moench-radix-revision-1\_en.pdf](https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-echinacea-purpurea-l-moench-radix-revision-1_en.pdf)  
12. Pharmacokinetic and pharmacodynamic interactions of echinacea ..., accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC2856051/](https://pmc.ncbi.nlm.nih.gov/articles/PMC2856051/)  
13. A Practical Perspective on the Use of Botanicals During the COVID-19 Pandemic: From Proven to Potential Interactions \- PubMed Central, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8787711/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8787711/)  
14. Echinacea Purpurea Significantly Induces Cytochrome P450 3A ..., accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC3407958/](https://pmc.ncbi.nlm.nih.gov/articles/PMC3407958/)  
15. The effect of Echinacea purpurea on the pharmacokinetics of ..., accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC3769673/](https://pmc.ncbi.nlm.nih.gov/articles/PMC3769673/)  
16. Flavonoids for Treating Viral Acute Respiratory Tract Infections: A Systematic Review and Meta-Analysis of 30 Randomized Controlled Trials \- PubMed Central, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8888526/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8888526/)  
17. Evaluation of echinacea for the prevention and treatment of the common cold: a meta-analysis \- PMC \- PubMed Central, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC7106401/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7106401/)  
18. Randomised, Double Blind, Placebo-Controlled Trial of Echinacea Supplementation in Air Travellers \- NIH, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC3249603/](https://pmc.ncbi.nlm.nih.gov/articles/PMC3249603/)  
19. Echinacea reduces antibiotic usage in children through respiratory tract infection prevention: a randomized, blinded, controlled clinical trial \- PubMed Central, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8028575/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8028575/)  
20. Safety and efficacy of echinacea (echinacea augustafolia, E ..., accessed November 5, 2025, [https://www.researchgate.net/publication/6710910\_Safety\_and\_efficacy\_of\_echinacea\_echinacea\_augustafolia\_E\_purpurea\_and\_E\_pallida\_during\_pregnancy\_and\_lactation](https://www.researchgate.net/publication/6710910_Safety_and_efficacy_of_echinacea_echinacea_augustafolia_E_purpurea_and_E_pallida_during_pregnancy_and_lactation)  
21. Herb–Drug Interaction in Inflammatory Diseases: Review of Phytomedicine and Herbal Supplements \- PMC \- PubMed Central, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8951360/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8951360/)  
22. Viral Upper Respiratory Infection \- PMC \- PubMed Central, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC7315336/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7315336/)  
23. The Long History of Vitamin C: From Prevention of the Common Cold to Potential Aid in the Treatment of COVID-19 \- Frontiers, accessed November 5, 2025, [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.574029/full](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.574029/full)  
24. Ctma 2018 | PDF | Nonverbal Communication \- Scribd, accessed November 5, 2025, [https://www.scribd.com/document/695736747/CTMA-2018](https://www.scribd.com/document/695736747/CTMA-2018)  
25. Self-Care for Common Colds: The Pivotal Role of Vitamin D, Vitamin C, Zinc, and Echinacea in Three Main Immune Interactive Clusters (Physical Barriers, Innate and Adaptive Immunity) Involved during an Episode of Common Colds—Practical Advice on Dosages and on the Time to Take These Nutrients/Botanicals in order to Prevent or \- NIH, accessed November 5, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC5949172/](https://pmc.ncbi.nlm.nih.gov/articles/PMC5949172/)  
26. Medicinal properties of Echinacea: A critical review | Request PDF \- ResearchGate, accessed November 5, 2025, [https://www.researchgate.net/publication/10869710\_Medicinal\_properties\_of\_Echinacea\_A\_critical\_review](https://www.researchgate.net/publication/10869710_Medicinal_properties_of_Echinacea_A_critical_review)  
27. TOX/2024/43 Committee on the Toxicity of Chemicals in Food, Consumer Products and the Environment Discussion paper on the potent, accessed November 5, 2025, [https://cot.food.gov.uk/sites/default/files/2024-12/TOX-2024-43%20Echinacea%20final%20draft%20COT%20paper%20Acc%20V%20SO.pdf](https://cot.food.gov.uk/sites/default/files/2024-12/TOX-2024-43%20Echinacea%20final%20draft%20COT%20paper%20Acc%20V%20SO.pdf)  
28. Novel Echinacea formulations for the treatment of acute respiratory tract infections in adults—A randomized blinded controlled trial \- Frontiers, accessed November 5, 2025, [https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.948787/full](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.948787/full)